Table 2.
sAxl and AFP levels of the study population
| Group | No. | sAxl (pg/mL) | AFP (ng/mL) |
|---|---|---|---|
| HCC | 80 | 2,020 (1,546-2,526) | 162.3 (6.4-3,514.5) |
| LC | 80 | 1,505 (1,004-1,911)a) | 16.7 (3.5-79.7)a) |
| HBV | 80 | 489 (296-887)a),b) | 7.0 (3.2-124.6)a),b) |
| HC | 80 | 678 (469-893)a),b),c) | 2.6 (2.0-4.2)a),b),d) |
| AFP-positive HCC | 54 | 2,004 (1,554-2,469) | 627.6 (152.5-9,488.0) |
| AFP-negative HCC | 26 | 2,100 (1,442-2,717)e) | 3.9 (3.0-6.4)f) |
| BCLC (0+A) | 34 | 1,984 (1,532-2,511)g) | 91.1 (4.0-613.2)g) |
| BCLC (B) | 14 | 2,060 (1,399-2,724)g) | 682.4 (68.0-8,446.3)g) |
| BCLC (C) | 28 | 1,940 (1,546-2,335)g) | 229.0 (6.0-9,620.0)g) |
| BCLC (D) | 4 | 2,524 (1,784-3,817)g) | 852.5 (40.9-4,533.5)g) |
Values are presented as median (interquartile range). sAxl, soluble Axl; AFP, α-fetoprotein; HCC, hepatocellular carcinoma; LC, liver cirrhosis; HBV, hepatitis B virus infection; HC, healthy controls; BCLC, Barcelona Clinic Liver Cancer.
a)
p < 0.05 (vs. HCC),
b)
p < 0.05 (vs. LC),
c)
p > 0.05 (vs. HBV),
d)
p < 0.05 (vs. HBV),
e)
p > 0.05 (vs. AFP-positive HCC),
f)
p < 0.05 (vs. AFPpositive HCC),
g)
p > 0.05 (vs. BCLC(0+A)).